Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors.

Peripheral blood inflammatory indices, like the neutrophil-to-lymphocyte ratio (NLR), may reflect the host's pro-inflammatory status and systemic immune response to cancer-related inflammation. We reviewed 22 combined prognostic scores based on peripheral blood-derived inflammatory indices for aNSCLC patients treated with single-agent or combination immune-checkpoint inhibitors (ICI) as first-line or subsequent therapy lines and attempted evidence strength assessment and scoring. The Lung Immune Prognostic Index (LIPI), consisting of derived NLR and LDH, was the most studied score with validated prognostic value in over five thousand aNSCLC ICI-naïve or pretreated patients. The combination of NLR and tumour programmed-cell-death-ligand1 (PD-L1) expression showed a predictive value. The Lung-Immune-Prognostic score (LIPS) might help identify patients with poor performance status but a favourable outcome following first-line ICI. These non-expensive scores can help clinicians discuss the prognosis with aNSCLC patients approaching ICI, identify those less likely to benefit from single-agent ICI and orient future clinical research.

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement S.E.R. received honoraria as a speaker at scientific events and travel accommodation from Amgen, GSK, BMS, MSD. A.P. received personal fees from Roche, AstraZeneca and BMS. A.F. received personal fee from Roche, Pfizer, Astellas, AstraZeneca, MSD, Sanofi, Novartis and BMS. A.C. received speaker fees and grant consultancies by Astrazeneca, MSD, BMS, Roche, Novartis and EISAI. A.A. received personal fee from MSD Oncology, Roche, Takeada, Pfizer, Bristol-Myers Squibb, AstraZeneca, Eli-Lilly, Roche. Speaker Bureau: Eli-Lilly, AstraZeneca.PT: Advisory board with Astellas, Bayer, BMS, Ipsen, Janssen-Cilag, Merck, MSD, Pfizer, Roche and Sanofi; travel and conference expenses from Lilly, Janssen-Cilag and Sanofi. C.G. received personal fees from Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, Merck Sharp Dohme, Roche, Takeda; Advisory Board: Merck Sharp Dohme. A.R.N. declares no competing interests. E.A. received travel/accommodation/expenses from Mundipharma and Honoraria (self) from Sanofi Genzymes, Amgen. L.M.: Research grant/Funding (self): Bristol Myers Squibb, Boehringer Ingelheim, Amgen, Stilla, Inivata; Advisory/Consultancy: Roche, Takeda; Honoraria (self): Bristol Myers Squibb, Takeda, Roche, AstraZeneca; Travel/Accommodation/Expenses: Bristol Myers Squibb, Takeda, Roche, AstraZeneca; Non-remunerated activity/ies: AstraZeneca. G.L.B. received personal fees from AstraZeneca, Astellas, and travel and conference expenses from Janssen.